Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

Bissler JJ, Nonomura N, Budde K, Zonnenberg BA, Fischereder M, Voi M, Louveau AL, Herbst F, Bebin EM, Curatolo P, Zonta A, Belousova E.

PLoS One. 2018 Sep 7;13(9):e0201005. doi: 10.1371/journal.pone.0201005. eCollection 2018.

2.

Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.

Curatolo P, Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, de Vries PJ, Dlugos DJ, Fan J, Ridolfi A, Pelov D, Voi M, French JA.

Lancet Child Adolesc Health. 2018 Jul;2(7):495-504. doi: 10.1016/S2352-4642(18)30099-3. Epub 2018 May 24.

PMID:
30169322
3.

Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures.

Franz DN, Lawson JA, Yapici Z, Brandt C, Kohrman MH, Wong M, Milh M, Wiemer-Kruel A, Voi M, Coello N, Cheung W, Grosch K, French JA.

Epilepsia. 2018 Jun;59(6):1188-1197. doi: 10.1111/epi.14085. Epub 2018 May 4.

4.

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.

Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F.

Ann Oncol. 2018 Mar 1;29(3):707-714. doi: 10.1093/annonc/mdx764.

PMID:
29253068
5.

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC.

Cancer Sci. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9.

6.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

7.

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.

Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, Voi M, Peyrard S, Budde K.

PLoS One. 2017 Aug 9;12(8):e0180939. doi: 10.1371/journal.pone.0180939. eCollection 2017.

8.

Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.

Pavel ME, Chen D, He W, Cushman S, Voi M, de Vries EGE, Baudin E, Yao JC.

Pancreas. 2017 Jul;46(6):751-757. doi: 10.1097/MPA.0000000000000830.

PMID:
28609362
9.

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.

Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group.

Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24.

PMID:
28554173
10.

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC.

Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193.

PMID:
28444114
11.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.

Ann Oncol. 2017 Jun 1;28(6):1309-1315. doi: 10.1093/annonc/mdx078.

PMID:
28327907
12.

Reply to V. Amoroso et al.

Yao JC, Voi M, Lincy J, Pavel M.

J Clin Oncol. 2017 May 1;35(13):1488-1489. doi: 10.1200/JCO.2017.71.3875. Epub 2017 Jan 23. No abstract available.

PMID:
28113028
13.

ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis: Topic: Medical Oncology.

Yao J, Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Pacaud L, Ridolfi A, Singh S, Pavel M, Kulke M.

J Thorac Oncol. 2016 Nov;11(11S):S253. doi: 10.1016/j.jtho.2016.09.011. Epub 2016 Oct 28. No abstract available.

14.

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, You D, Viale A, Lee W, Hakimi AA, Berger MF, Socci ND, Cheng EH, Knox J, Voss MH, Voi M, Motzer RJ.

Eur Urol. 2017 Mar;71(3):405-414. doi: 10.1016/j.eururo.2016.10.007. Epub 2016 Oct 15.

15.

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Öberg K.

J Clin Oncol. 2016 Nov 10;34(32):3906-3913. doi: 10.1200/JCO.2016.68.0702. Epub 2016 Sep 30.

16.

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.

French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN.

Lancet. 2016 Oct 29;388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6.

17.

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.

JAMA Oncol. 2016 Oct 1;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279.

18.

Everolimus in ileum neuroendocrine tumours - Authors' reply.

Yao JC, Voi M, Rouyrre N, Singh S.

Lancet. 2016 Jul 16;388(10041):236-7. doi: 10.1016/S0140-6736(16)31045-5. No abstract available.

PMID:
27479568
19.

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.

Bono P, Oudard S, Bodrogi I, Hutson TE, Escudier B, Machiels JP, Thompson JA, Figlin RA, Ravaud A, Basaran M, Porta C, Bracarda S, Brechenmacher T, Lin C, Voi M, Grunwald V, Motzer RJ.

Clin Genitourin Cancer. 2016 Oct;14(5):406-414. doi: 10.1016/j.clgc.2016.04.011. Epub 2016 Apr 27.

20.

Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.

Zhu AX, Chen D, He W, Kanai M, Voi M, Chen LT, Daniele B, Furuse J, Kang YK, Poon RT, Vogel A, Chiang DY.

J Hepatol. 2016 Aug;65(2):296-304. doi: 10.1016/j.jhep.2016.04.015. Epub 2016 Apr 27.

PMID:
27130844
21.

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.

Voss MH, Chen D, Marker M, Hakimi AA, Lee CH, Hsieh JJ, Knox JJ, Voi M, Motzer RJ.

Br J Cancer. 2016 Mar 15;114(6):642-9. doi: 10.1038/bjc.2016.21. Epub 2016 Feb 23.

22.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group.

Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.

23.

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.

Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A, Wang J, Laliberte R, Voi M, Tolcher AW.

Clin Cancer Res. 2014 Oct 1;20(19):5032-40. doi: 10.1158/1078-0432.CCR-14-0570. Epub 2014 Aug 8.

24.

Does laboratory automation for the preanalytical phase improve data quality?

Lima-Oliveira G, Lippi G, Salvagno GL, Danese E, Montagnana M, Brocco G, Voi M, Picheth G, Guidi GC.

J Lab Autom. 2013 Oct;18(5):375-81. doi: 10.1177/2211068213488892. Epub 2013 May 17.

PMID:
23686657
25.

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.

Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, Xu W, Cai X, Voi M, Savagner P, Lai CJ.

Mol Cancer Ther. 2013 Jun;12(6):925-36. doi: 10.1158/1535-7163.MCT-12-1045. Epub 2013 Mar 27.

26.

Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.

Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X, Voi M.

Clin Cancer Res. 2012 Aug 1;18(15):4104-13. doi: 10.1158/1078-0432.CCR-12-0055. Epub 2012 Jun 12.

27.

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR.

Clin Cancer Res. 2009 Oct 1;15(19):6232-40. doi: 10.1158/1078-0432.CCR-09-0224. Epub 2009 Sep 29.

28.

Overcoming kinase resistance in chronic myeloid leukemia.

Lee F, Fandi A, Voi M.

Int J Biochem Cell Biol. 2008;40(3):334-43. Review.

PMID:
18401881
29.

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

Sessa C, Perotti A, Lladò A, Cresta S, Capri G, Voi M, Marsoni S, Corradino I, Gianni L.

Ann Oncol. 2007 Sep;18(9):1548-53.

PMID:
17761711
30.

Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G.

Clin Cancer Res. 2006 Mar 15;12(6):1760-7.

31.

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA.

J Clin Oncol. 2005 Apr 20;23(12):2831-9.

PMID:
15837997
32.

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.

Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, Baselga J.

J Clin Oncol. 2005 Apr 10;23(11):2521-33. Epub 2005 Feb 14. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5350.

PMID:
15710949
33.

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.

Camps C, Felip E, Sanchez JM, Massuti B, Artal A, Paz-Ares L, Carrato A, Alberola V, Blasco A, Baselga J, Astier L, Voi M, Rosell R; Spanish Lung Cancer Group.

Ann Oncol. 2005 Apr;16(4):597-601. Epub 2005 Jan 31.

PMID:
15684226
34.

Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.

Douillard JY, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey J, Ottaway J, Young K, Vreckem AV, Seymour L.

Lung Cancer. 2004 Dec;46(3):361-8.

PMID:
15541822
35.

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.

Mackay HJ, Hoekstra R, Eskens FA, Loos WJ, Crawford D, Voi M, Van Vreckem A, Evans TR, Verweij J.

Clin Cancer Res. 2004 Apr 15;10(8):2636-44.

36.

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

Sessa C, Perotti A, Salvatorelli E, Minotti G, Viganò L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, Voi M, Marsoni S, Gianni L.

Eur J Cancer. 2004 Mar;40(4):563-70.

PMID:
14962724
37.

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K; National Cancer Institute of Canada Clinical Trials Group Study MA.19.

J Clin Oncol. 2004 Jan 15;22(2):269-76.

PMID:
14722035
38.

Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.

Plummer R, Ghielmini M, Calvert P, Voi M, Renard J, Gallant G, Gupta E, Calvert H, Sessa C.

Clin Cancer Res. 2002 Sep;8(9):2788-97.

39.

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.

Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R.

Cancer. 1999 Mar 15;85(6):1261-8.

PMID:
10189130
40.

[A phase II multicenter study of gemcitabine in non small cell lung cancers].

Le Chevalier T, Gottfried M, Gatzemeier U, Shepherd F, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Voi M, Ponzio A.

Bull Cancer. 1997 Mar;84(3):282-8. French.

41.

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.

Copley-Merriman C, Corral J, King K, Whiteside R, Voi M, Dorr FA, McDonald RC.

Lung Cancer. 1996 Feb;14(1):45-61.

PMID:
8696720
42.

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.

Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M.

Eur J Cancer. 1996 Feb;32A(2):243-8.

PMID:
8664035
43.

Cefaclor advanced formulation versus cefaclor in the treatment of pneumonia.

Casali L, Voi M, Janssen CJ, Olovich KG, Dere WH.

Clin Ther. 1992 Jul-Aug;14(4):570-7.

PMID:
1525791
44.

Cefaclor AF in the treatment of streptococcal pharyngitis/tonsillitis.

Derriennic M, Voi M, Thoren LM, Black SA, Dere WH.

Postgrad Med J. 1992;68 Suppl 3:S43-6; discussion S46-8.

PMID:
1287618

Supplemental Content

Support Center